HAE Preventive Therapy Not Cost-effective, Prices Need to Drop 50%

HAE Preventive Therapy Not Cost-effective, Prices Need to Drop 50%

304808

HAE Preventive Therapy Not Cost-effective, Prices Need to Drop 50%

The prices of three approved preventive treatments — Cinryze, Haegarda, and Takhzyro (lanadelumab) — for hereditary angioedema (HAE) must be reduced by more than half for these medications to be cost-effective. Those are the conclusions of a new report published by the Institute for Clinical and Economic Review, known as ICER, an independent non-profit research organization that serves as a healthcare watchdog. The report was conducted in collaboration with Aetion and the University of Washington. “All…

You must be logged in to read/download the full post.